ICER Misses the Numbers That Matter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
Categorized in: Analysis
Recent Blog Posts
Why Don’t Insurers Take Obesity Seriously?
June 30, 2022
Feds Poised to Take a Hard Look at Pharmacy Benefit Managers
June 28, 2022
Federal Court Upholds West Virginia Law that Reigns in “Bad Drug” Ads
June 24, 2022